Pseudomonas aeruginosa: Difference between revisions

From IDWiki
Pseudomonas aeruginosa
()
()
Line 37: Line 37:
=== Multidrug Resistant Isolates ===
=== Multidrug Resistant Isolates ===


* Consider any of the following options
* Consider any of the following options:
* [[Amikacin]] 20 mg/kg IV once, followed by dosing per levels (see [[Aminoglycosides#Dosing|Aminoglycosides]])
** [[Amikacin]] 20 mg/kg IV once, followed by dosing per levels (see [[Aminoglycosides#Dosing|Aminoglycosides]])
* [[Cefiderocol]] 2 g IV 18h infused over 3 hours
** [[Cefiderocol]] 2 g IV 18h infused over 3 hours
* [[Ceftazidime-avibactam]] 2.5 g IV q8h infused over 3 hours
** [[Ceftazidime-avibactam]] 2.5 g IV q8h infused over 3 hours
* [[Ceftolozane-tazobactam]] 3 g IV q8h infused over 3 hours
** [[Ceftolozane-tazobactam]] 3 g IV q8h infused over 3 hours
* [[Colistin]]
** [[Colistin]]
* [[Gentamicin]] 7 mg/kg IV once followed by dosing per levels (see [[Aminoglycosides#Dosing|Aminoglycosides]])
** [[Gentamicin]] 7 mg/kg IV once followed by dosing per levels (see [[Aminoglycosides#Dosing|Aminoglycosides]])
* [[Imipenem-relebactam]] 1.25 g IV q6h infused over 30 minutes
** [[Imipenem-relebactam]] 1.25 g IV q6h infused over 30 minutes
* [[Plazomicin]] 15 mg/kg IV once followed by dosing per levels (see [[Aminoglycosides#Dosing|Aminoglycosides]])
** [[Plazomicin]] 15 mg/kg IV once followed by dosing per levels (see [[Aminoglycosides#Dosing|Aminoglycosides]])
* [[Polymixin B]]
** [[Polymixin B]]
* [[Tobramycin]] 7 mg/kg IV once followed by dosing per levels (see [[Aminoglycosides#Dosing|Aminoglycosides]])
** [[Tobramycin]] 7 mg/kg IV once followed by dosing per levels (see [[Aminoglycosides#Dosing|Aminoglycosides]])
*Preference for [[ceftolozane-tazobactam]], [[ceftazidime-avibactam]], and [[imipenem-relebactam]], as well as [[cefiderocol]] if UTI


{{DISPLAYTITLE:''Pseudomonas aeruginosa''}}
{{DISPLAYTITLE:''Pseudomonas aeruginosa''}}

Revision as of 19:27, 24 November 2021

Background

Microbiology

  • Oxidase positive, non-fermenting Gram-negative bacillus

Mechanisms of Resistance

Epidemiology

  • Loves moist and wet environments
  • Causes healthcare-associated infections
    • UTI, SSI, bacteremia, HAP, VAP
    • Especially common in cystic fibrosis

Treatment

  • Refer to antipseudomonal antibiotics for specific treatment options
  • Double coverage (ß-lactam + non-ß-lactam) in cases of severe infection in order to ensure activity against the infection

Multidrug Resistant Isolates

References

  1. ^  D. M. Livermore. Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare?. Clinical Infectious Diseases. 2002;34(5):634-640. doi:10.1086/338782.